Related Experiment Videos
Increased platelet and coagulatory activity in peripheral atherosclerosis flow mediated platelet function is a
C B Reininger1, J Graf, A J Reininger
1Klinikum Innenstadt, Ludwig-Maximilians Universität München.
Insights
Peripheral arterial disease (PAD) involves high thrombosis risk. Stagnation Point Flow Adhesio-Aggregometry (SPAA) effectively measures increased platelet and coagulatory activity in PAD patients, outperforming conventional methods.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biomedical Engineering
Background:
- Atherosclerosis and thrombosis are central to peripheral arterial disease (PAD).
- Systemic hemostatic derangements are suspected contributors to high thrombosis risk in PAD.
- Understanding flow's role in platelet activation is crucial for PAD management.
Purpose of the Study:
- To evaluate the clinical efficacy of Stagnation Point Flow Adhesio-Aggregometry (SPAA) in assessing platelet and coagulatory activity in PAD patients.
- To compare SPAA with conventional aggregometry and other hemostatic markers in detecting PAD.
- To investigate the impact of aspirin therapy on measured parameters.
Main Methods:
- 62 nondiabetic PAD patients and 66 healthy volunteers were studied.
- Stagnation Point Flow Adhesio-Aggregometry (SPAA) was used for real-time assessment of platelet adhesion/aggregation under low-shear flow.
- Conventional aggregometry, fibrinogen, fibrin monomer (FM), D-Dimer, and thrombin-antithrombin-complex (TAT) were also assessed.
Main Results:
- Conventional aggregometry showed no significant differences between PAD patients and controls.
- SPAA revealed significantly increased platelet function (p < 0.001) in PAD patients.
- Elevated levels of fibrinogen (p < 0.001), FM (p < 0.001), TAT (p < 0.02), and D-Dimer (p < 0.001) were observed in PAD patients, unaffected by aspirin.
- SPAA demonstrated high sensitivity (96%) and specificity (95%) for PAD detection.
Conclusions:
- Flow-mediated platelet adhesion and aggregation, measured by SPAA, are significantly increased in PAD.
- SPAA is a highly sensitive and specific tool for detecting PAD, surpassing conventional markers.
- These findings highlight SPAA's utility in understanding platelet-related mechanisms and guiding therapeutic strategies in PAD.
Abstract:
The importance of flow in both athero- and thrombogenesis is well established. In peripheral arterial disease (PAD) atherosclerosis is disseminated, thrombosis risk high and systemic hemostatic derangement believed contributory. We studied platelet and coagulatory activity in PAD patients, thereby evaluating the clinical efficacy of Stagnation Point Flow Adhesio-Aggregometry (SPAA). SPAA provides real-time quantitative assessment of platelet adhesion and aggregation under convective, low-shear flow conditions. 62 nondiabetic PAD patients and 66 healthy volunteers were examined, whereby SPAA and conventional aggregometry were performed and circulating fibrinogen, fibrin monomer (FM), the fibrin degradation product D-Dimer and thrombin-antithrombin-complex (TAT) assessed. Conventional aggregometry detected no differences between patients and controls. SPAA-measured platelet function (p < 0.001), fibrinogen (p < 0.001), FM (p < 0.001), TAT (p < 0.02) and D-Dimer (p < 0.001) were significantly increased in patients and not effected by aspirin therapy. Respective sensitivity and specificity in detecting PAD was as follows: SPAA (96%/95%), fibrinogen (36%/92%), FM (46%/88%), TAT (40%/73%), D-Dimer (75%/80%). Increased platelet and coagulatory activity was verified in PAD, whereby flow-mediated platelet adhesion and aggregation proved the most sensitive and specific parameter. These findings indicate the usefulness of SPAA for delineating platelet-related disease mechanisms and evaluating therapeutic strategies to prevent platelet activation.